查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1351057

到 2030 年膀胱過動症治療市場預測 - 按類型、疾病類型、配銷通路和地區進行的全球分析

Overactive Bladder Treatment Market Forecasts to 2030 - Global Analysis By Type, Disease Type, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球膀胱過動症治療市場規模將達到 36 億美元，預計到 2030 年將達到 48 億美元，預測期內年複合成長率為 6.2%。

膀胱過動症症 (OAB) 會導致頻繁且意外的排尿衝動，這可能是控制的挑戰。您可能會在白天或晚上頻繁地想小便，或者您可能會無意中漏尿。醫療專業人員可以透過分析症狀並檢查骨盆和直腸附近的器官來識別膀胱過動症。有多種方法可以治療膀胱過動症。改變某些行為、使用藥物和刺激神經都是可能的治療方法。

根據2021年6月發表在《Krager Journal》上的一篇題為「Mechanism and Priority of Botulinum Neurotoxin A vs Sacral Neuromodulation」的難治性膀胱過動症論文，膀胱過動症在全球極為常見，整體患病11.8%。

神經系統疾病患病上升

多種藥物用於治療神經系統疾病，包括抗癲癇藥物、抗精神病藥物、止痛藥和抗膽鹼能藥物。人口高齡化正在推動市場擴張，同時開發新藥和設備的支出也在增加。此外，政府法規機構和私人組織預計將發起宣傳活動，以增加公眾對早期殘疾診斷的了解。此外，由於開發平臺強勁，有效藥物可望很快進入市場，推動市場擴張。

頻繁的產品召回

很大一部分人口患有膀胱過動症，這是一種對生活品質有負面影響的慢性疾病。 OAB 治療藥物的頻繁召回可能會阻礙未來年度的市場擴張。由於製造問題，Cipla 於 2021 年 6 月在美國召回了 7,228 瓶琥珀酸索利那新片劑。主要製藥公司頻繁召回自家公司產品，阻礙了市場擴張。

研發費用增加和新治療方法的引入

製藥和生物製藥公司目前正在投資用於治療膀胱過動症的尖端藥物，預計將在整個預測期內推出。此外，超過 30 種 OAB 治療候選藥物目前正處於臨床階段。分為3個二期項目、7個三期項目和16個四期項目。由於如此強大的產品線以及最終推出的其他藥物和治療方法，預計膀胱過動症治療市場將會成長。三星醫療中心正在研究 OAB 患者的潛在生物標記物，包括三磷酸腺苷 (ATP)、前列腺素 E2 (PGE2) 和神經生長因子 (NGF)。 OAB 治療市場的參與者有望從這些進步帶來的顯著成長預測中受益。

缺乏普及知識

阻礙市場拓展的要素之一是階段開發或預註冊階段的藥品數量較少。此外，補充療法的可用性、新興市場缺乏醫療基礎設施以及缺乏合格的醫療專家阻礙了整個預測期內的市場擴張。產品召回和嚴格的政府法規也阻礙了產業擴張。

COVID-19 的影響：

COVID-19的爆發對膀胱過動症領域的全球擴張產生了有益的影響。 COVID-19相關膀胱炎（CAC）大大加劇了患者的膀胱功能障礙，這也導致了其他器官的特定問題。這對疫情期間和疫情後的膀胱過動症藥物市場產生了積極影響。同時，COVID-19 大流行已成為醫療保健系統面臨的最大挑戰之一。 COVID-19大流行的爆發導致生產設施部分或完全關閉，美國、中國、日本、印度和德國等主要國家都處於長期封鎖措施之下。這對膀胱過動症藥物的生產產生了輕微影響。

預計抗膽鹼能藥物領域在預測期內將是最大的

由於抗膽鹼能藥物是治療膀胱過動症症候群的主要選擇，抗膽鹼能藥物市場預計將出現良好的成長。此外，美國食品藥物管理局對學名藥的快速產品核可正在支持抗膽鹼能藥物市場的擴張。此外，與侵入性手術和口服藥物相比，最終用戶對肉毒桿菌治療的偏好預計將增加預測期內膀胱過動症治療市場同一領域的發展潛力。

特發性膀胱過動症領域預計在預測期內年複合成長率最高

由於患者特發性膀胱過動症領域率上升以及對特發性特發性膀胱膀胱過動症症治療的需求不斷增加，預計特發性膀胱過動症部分在預測期內將出現最高的年複合成長率。另一方面，由於預計會增加膀胱過動症領域的神經系統疾病的增加，預計神經膀胱過動症症領域將在預測期內以最快的速度擴大。

比最大的地區

由於醫療保健領域強勁，預計北美將在預測期內佔據最大的市場佔有率。此外，還有要素，例如膀胱過動症治療的報銷、隨著高齡化而增加的發病率以及該地區存在重要的行業參與者。此外，預計該市場將受益於老年人口的成長以及該地區人口高齡化的大量存在。

複合年複合成長率最高的地區：

由於該地區製藥公司的存在以及中國和印度等人口大國購買力的不斷上升，預計歐洲在預測期內將出現最高的年複合成長率。此外，醫療保健支出的增加以及採用高科技製造技術來提高膀胱過動症治療藥物的產量對於該地區的藥品生產商來說是充足的，該地區擁有最大的製藥部門和最大的藥品供應量，並且很容易取得原料。此外，工業基礎設施正在擴大，可支配收入正在增加，國內公司正在該地區建立業務。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球膀胱過動症治療市場：依類型

  • 抗膽鹼能藥物
    • 達非那新
    • 非索羅定
    • 奧昔布寧
    • 索利那新
    • 托特羅定
    • 曲司品
    • 其他抗膽鹼能藥物
  • 米拉貝隆
  • 肉毒桿菌
  • 神經調節
  • 其他治療方法

第6章 全球膀胱過動症治療市場：依疾病類型

  • 神經源性膀胱過動症
    • 帕金森氏症
    • 中風
    • 多發性硬化症
    • 脊髓損傷
  • 特發性膀胱過動症
  • 其他類型的疾病

第7章 全球膀胱過動症治療市場：按配銷通路

  • 醫院藥房
  • 藥局和零售藥局
  • 線上提供者
  • 其他配銷通路

第8章 全球膀胱過動症治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Dr. Reddy's Laboratories Ltd
  • Pfizer Inc.
  • Cipla Ltd
  • Lupin
  • Sun Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • Alembic Pharmaceuticals Limited
  • Sumitomo Pharma Co., Ltd
  • Teva Pharmaceutical Industries Limited
  • Johnson & Johnson Services, Inc.
  • Medtronic
  • Sanofi
  • Uro Medical
  • Urovant Sciences
  • Macleods Pharmaceuticals Ltd
  • Endo International PLC
  • Hisamitsu Pharmaceutical Co., Inc.
  • Laborie
Product Code: SMRC23744

According to Stratistics MRC, the Global Overactive Bladder Treatment Market is accounted for $3.6 billion in 2023 and is expected to reach $4.8 billion by 2030 growing at a CAGR of 6.2% during the forecast period. The condition known as overactive bladder (OAB) results in frequent, unexpected urinal urges that can be challenging to control. One can experience frequent urges to urinate during the day and at night, as well as inadvertent pee loss. A medical professional can identify overactive bladder by analyzing the symptoms and physically inspecting the organs close to the pelvic and rectum. Various treatments are available to treat hyperactive bladder. Changing certain behaviors, using medicine, and nerve stimulation are all possible treatments.

According to the article published in Krager Journal titled "Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation" for refractory overactive bladder, in June 2021, overactive bladder is highly prevalent worldwide and found that its overall prevalence was 11.8%.

Market Dynamics:

Driver:

Rising prevalence of neurological conditions

Several drugs, including antiepileptics, antipsychotics, analgesics, and anticholinergics, are used to treat neurological illnesses. The aging population is driving market expansion, along with increased spending on the development of new drugs and devices. Additionally, government regulatory agencies and private groups are projected to launch awareness efforts to raise public knowledge of early disorder diagnosis. Additionally, effective medications will soon enter the market as a result of a robust development pipeline, which is expected to fuel market expansion.

Restraint:

Frequent product recalls

A large portion of the population suffers from overactive bladder, a chronic medical condition that has an adverse effect on quality of life. The expansion of the market could be hampered in the coming years by frequent recalls of OAB-treating medications. Due to production problems, Cipla recalled 7,228 bottles of Solifenacin Succinate tablets in the US in June 2021. Leading pharmaceutical corporations frequently recalling their products hurts the market's expansion.

Opportunity:

Increasing R&D spending and the introduction of new treatments

Pharmaceutical and biopharmaceutical companies are now investing in cutting-edge medicines for the treatment of overactive bladders, which are anticipated to be introduced throughout the projected period. In addition, more than 30 OAB candidates are presently in clinical development pathways. These are divided into three Phase II, seven Phase III, and sixteen Phase IV projects. The market for treating overactive bladder is anticipated to grow as a result of this strong pipeline and the eventual introduction of additional medications and therapies. Samsung Medical Center is researching potential biomarkers in OAB patients, including adenosine triphosphate (ATP), prostaglandin E2 (PGE2), and nerve growth factor (NGF). Players in the OAB treatment market can anticipate benefiting from significant growth prospects as a result of such advances.

Threat:

Lack of knowledge about its prevalence

One of the things preventing the market from expanding is the dearth of medications in Phase III development or the pre-registration stages. Additionally, throughout the forecast period, market expansion is hampered by the availability of complementary therapies, a lack of healthcare infrastructure in developing nations, and a shortage of qualified specialists. Recalls of products and stringent government regulations are also impeding industry expansion.

COVID-19 Impact:

The COVID-19 outbreak had a beneficial effect on the expansion of the overactive bladder sector globally. The patient's bladder dysfunction was greatly exacerbated by COVID-19 association cystitis (CAC), which also caused issues unique to other organs. This had a favorable effect on the market for treatments for overactive bladder both during and after the epidemic. The COVID-19 epidemic, on the other hand, presented one of the greatest difficulties for the healthcare system. Due to the protracted lockdown in important nations like the United States, China, Japan, India, and Germany, the COVID-19 pandemic outbreak has resulted in the partial or total suspension of production facilities. This had some impact on the production of drugs for overactive bladder.

The anticholinergics segment is expected to be the largest during the forecast period

The anticholinergics segment is estimated to have a lucrative growth, due to the primary choice of medications for treating overactive bladder syndrome is anticholinergics. Additionally, the U.S. Food and Drug Administration's quick product approvals for generic medications support the expansion of the anticholinergic market. Additionally, it has been predicted that a movement in end users' preferences of botox treatment over invasive surgery or oral drugs will increase the segment's development potential in the overactive bladder therapeutics market over the course of the projection year.

The idiopathic overactive bladder segment is expected to have the highest CAGR during the forecast period

The idiopathic overactive bladder segment is anticipated to witness the highest CAGR growth during the forecast period, due to rising rates of idiopathic overactive bladder in patients and rising demand for overactive bladder drugs for the treatment of idiopathic overactive bladder. The sector for neurogenic overactive bladder, on the other hand, is anticipated to expand at the quickest rate during the forecast period due to the rise in neurological diseases, which is predicted to increase the incidence of overactive bladder.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to its robust healthcare sector. In addition, factors such as reimbursement for overactive bladder treatment, an increasing incidence of the condition with advancing age, and the presence of significant industry players in the region. Moreover, the market is set to benefit from the growing elderly population, and the substantial presence of an aging demographic in the region.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, due to the presence of pharmaceutical businesses in the area and the rise in the purchasing power of populous nations like China and India. Moreover, an increase in medical spending and the use of high-tech manufacturing techniques to enhance the production of drugs for treating overactive bladder with largest pharmaceutical sector and the largest supply of medicines, with easy access to a plentiful supply of raw materials for pharmaceutical product producers in this region. In addition, because of the expanding industrial infrastructure, rising disposable incomes, and established domestic company presence in the area.

Key players in the market:

Some of the key players profiled in the Overactive Bladder Treatment Market include: Dr. Reddy's Laboratories Ltd, Pfizer Inc. , Cipla Ltd, Lupin, Sun Pharmaceutical Industries Ltd., Astellas Pharma Inc., AbbVie Inc., Alembic Pharmaceuticals Limited, Sumitomo Pharma Co., Ltd, Teva Pharmaceutical Industries Limited, Johnson & Johnson Services, Inc., Medtronic, Sanofi, Uro Medical, Urovant Sciences, Macleods Pharmaceuticals Ltd, Endo International PLC, Hisamitsu Pharmaceutical Co., Inc. and Laborie

Key Developments:

In July 2022, Dr. Reddy's Laboratories introduced fesoterodine fumarate extended-release tablets, a therapeutic generic equivalent to Pfizer's Toviaz (fesoterodine fumarate) ER tablets in the United States for the treatment of overactive bladder.

In April 2022, Dr Reddy's launched generic Methylprednisolone Sodium Succinate for injection in US, The injection is the generic equivalent of SOLUMEDROL and has been approved by the US Food and Drug Administration (USFDA), the company said in a regulatory filing.

In May 2022, Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., presented data from the Phase 3 EMPOWUR Extension Study of GEMTESA(vibegron) 75 mg overactive bladder therapy.

Treatments Covered:

  • Anticholinergics
  • Mirabegron
  • BOTOX
  • Neuromodulation
  • Other Treatments

Disease Types Covered:

  • Neurogenic Overactive Bladder
  • Idiopathic Overactive Bladder
  • Other Disease Types

Distribution Channels Covered:

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Overactive Bladder Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Anticholinergics
    • 5.2.1 Darifenacin
    • 5.2.2 Fesoterodine
    • 5.2.3 Oxybutynin
    • 5.2.4 Solifenacin
    • 5.2.5 Tolterodine
    • 5.2.6 Trospium
    • 5.2.7 Other Anticholinergics
  • 5.3 Mirabegron
  • 5.4 BOTOX
  • 5.5 Neuromodulation
  • 5.6 Other Treatments

6 Global Overactive Bladder Treatment Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Neurogenic Overactive Bladder
    • 6.2.1 Parkinson's disease
    • 6.2.2 Strokes
    • 6.2.3 Multiple Sclerosis
    • 6.2.4 Spinal Cord Injuries
  • 6.3 Idiopathic Overactive Bladder
  • 6.4 Other Disease Types

7 Global Overactive Bladder Treatment Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Drug Stores and Retail Pharmacies
  • 7.4 Online Providers
  • 7.5 Other Distribution Channels

8 Global Overactive Bladder Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Dr. Reddy's Laboratories Ltd
  • 10.2 Pfizer Inc.
  • 10.3 Cipla Ltd
  • 10.4 Lupin
  • 10.5 Sun Pharmaceutical Industries Ltd.
  • 10.6 Astellas Pharma Inc.
  • 10.7 AbbVie Inc.
  • 10.8 Alembic Pharmaceuticals Limited
  • 10.9 Sumitomo Pharma Co., Ltd
  • 10.10 Teva Pharmaceutical Industries Limited
  • 10.11 Johnson & Johnson Services, Inc.
  • 10.12 Medtronic
  • 10.13 Sanofi
  • 10.14 Uro Medical
  • 10.15 Urovant Sciences
  • 10.16 Macleods Pharmaceuticals Ltd
  • 10.17 Endo International PLC
  • 10.18 Hisamitsu Pharmaceutical Co., Inc.
  • 10.19 Laborie

List of Tables

  • Table 1 Global Overactive Bladder Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Overactive Bladder Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Overactive Bladder Treatment Market Outlook, By Anticholinergics (2021-2030) ($MN)
  • Table 4 Global Overactive Bladder Treatment Market Outlook, By Darifenacin (2021-2030) ($MN)
  • Table 5 Global Overactive Bladder Treatment Market Outlook, By Fesoterodine (2021-2030) ($MN)
  • Table 6 Global Overactive Bladder Treatment Market Outlook, By Oxybutynin (2021-2030) ($MN)
  • Table 7 Global Overactive Bladder Treatment Market Outlook, By Solifenacin (2021-2030) ($MN)
  • Table 8 Global Overactive Bladder Treatment Market Outlook, By Tolterodine (2021-2030) ($MN)
  • Table 9 Global Overactive Bladder Treatment Market Outlook, By Trospium (2021-2030) ($MN)
  • Table 10 Global Overactive Bladder Treatment Market Outlook, By Other Anticholinergics (2021-2030) ($MN)
  • Table 11 Global Overactive Bladder Treatment Market Outlook, By Mirabegron (2021-2030) ($MN)
  • Table 12 Global Overactive Bladder Treatment Market Outlook, By BOTOX (2021-2030) ($MN)
  • Table 13 Global Overactive Bladder Treatment Market Outlook, By Neuromodulation (2021-2030) ($MN)
  • Table 14 Global Overactive Bladder Treatment Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 15 Global Overactive Bladder Treatment Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 16 Global Overactive Bladder Treatment Market Outlook, By Neurogenic Overactive Bladder (2021-2030) ($MN)
  • Table 17 Global Overactive Bladder Treatment Market Outlook, By Parkinson's disease (2021-2030) ($MN)
  • Table 18 Global Overactive Bladder Treatment Market Outlook, By Strokes (2021-2030) ($MN)
  • Table 19 Global Overactive Bladder Treatment Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 20 Global Overactive Bladder Treatment Market Outlook, By Spinal Cord Injuries (2021-2030) ($MN)
  • Table 21 Global Overactive Bladder Treatment Market Outlook, By Idiopathic Overactive Bladder (2021-2030) ($MN)
  • Table 22 Global Overactive Bladder Treatment Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 23 Global Overactive Bladder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 24 Global Overactive Bladder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 25 Global Overactive Bladder Treatment Market Outlook, By Drug Stores and Retail Pharmacies (2021-2030) ($MN)
  • Table 26 Global Overactive Bladder Treatment Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 27 Global Overactive Bladder Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.